eTheRNA Manufacturing, a specialist RNA process developer, is introducing a Lipid Nanoparticle (LNP) formulation development and production service, aimed to support the discovery and early preclinical development of RNA-based therapeutics and vaccines.
The service uses the company’s proprietary lipid libraries and proprietary formulations to facilitate targeted delivery and tailored biodistribution solutions.
The company says its LNP formulation platforms employ several mRNA and lipid mixing technologies, providing the market with alternatives to the formulations in use currently. It can also provide phase-appropriate analytical development in parallel with manufacturing process optimisation to help customers with their RNA product development programs.
Bernard Sagaert, COO and Senior VP of Manufacturing, eTheRNA Manufacturing, said: “The recent COVID pandemic has facilitated the rapid development and approval of the first-wave of COVID-19 RNA vaccines, which has led some people to underestimate some of the complexities of developing a RNA-based therapeutic or vaccine.
“Development of efficacious and safe RNA-based medicines requires a unique set of skills and resources to simultaneously advance both the active drug substance and the correct formulation required for the drug product. Through our long-established focus on RNA manufacture and delivery, and associated proprietary technologies, we have engineered libraries of custom lipids, which enables our LNP formulation team to design the most appropriate LNP for your mRNA application.”